NEXGEL, Inc. (NXGL)
| Market Cap | 6.96M -71.1% |
| Revenue (ttm) | 11.67M +73.4% |
| Net Income | -2.88M |
| EPS | -0.38 |
| Shares Out | 8.14M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 244,144 |
| Open | 0.9231 |
| Previous Close | 0.9555 |
| Day's Range | 0.8400 - 0.9231 |
| 52-Week Range | 0.7033 - 3.2500 |
| Beta | 0.62 |
| Analysts | Strong Buy |
| Price Target | 2.00 (+133.95%) |
| Earnings Date | Mar 23, 2026 |
About NXGL
NEXGEL, Inc. manufactures and sells high water content, electron beam cross-linked, and aqueous polymer hydrogels and gels for wound care, medical diagnostics, transdermal drug delivery, and cosmetics in the United States. It operates through two segments: Nexgel and CG labs. The company offers over-the-counter remedy solutions, such as blister and pain applications; and beauty and cosmetic solutions. It also developing NEXDrape, an incise surgical drape designed for patients with impaired skin; and NEXDerm, an adhesive tape designed to secure ... [Read more]
Financial Performance
In 2024, NEXGEL's revenue was $8.69 million, an increase of 112.47% compared to the previous year's $4.09 million. Losses were -$3.28 million, 3.93% more than in 2023.
Financial StatementsAnalyst Summary
According to one analyst, the rating for NXGL stock is "Strong Buy" and the 12-month stock price target is $2.0.
News
NEXGEL Announces Consideration Terms of Agreement to License and Acquire Portfolio of Commercial-Stage Regenerative Biomaterial Products
Consideration for portfolio will consist of a $15 million upfront cash payment and potentially an additional $20 million in milestone payments based on net sales targets related to the portfolio
NEXGEL Signs Definitive Agreement to License and Acquire Transformative Portfolio of Commercial-Stage Regenerative Biomaterial Products
Transaction expected to approximately triple NEXGEL's annual revenue to about $35 million and is expected to make the Company immediately profitable upon closing
EXCLUSIVE: NexGel To Acquire Regenerative Biomaterial Portfolio From Celularity, Expects To Triple Revenue
The transaction represents the most significant milestone in the company's history.
NEXGEL Announces Spin-Off of Drug Delivery Program into NexGelRx
NEXGEL shareholders will receive a non-dilutive 19.99% equity interest in NexGelRx up to $8 million of capital investment in spin-off
NEXGEL, Inc. (NXGL) Q3 2025 Earnings Call Transcript
NEXGEL, Inc. ( NXGL) Q3 2025 Earnings Call November 11, 2025 4:30 PM EST Company Participants Adam Levy - CEO, President & Director Joseph McGuire - Chief Financial Officer Conference Call Participan...
NEXGEL Reports Third Quarter 2025 Financial Results
LANGHORNE, Pa., Nov. 11, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ult...
NEXGEL, Inc. (NXGL) Q2 2025 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q2 2025 Earnings Conference Call August 12, 2025 4:30 PM ET Company Participants Adam R. Levy - CEO, President & Director Joseph F.
NEXGEL to Report Second Quarter 2025 Financial Results on August 12th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL Announces $950,000 Registered Direct Offering and Concurrent Private Placement
LANGHORNE, Pa., Aug. 01, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL and STADA AG Announce Expansion of Partnership for North America
LANGHORNE, Pa., July 14, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and...
NEXGEL, Inc. (NXGL) Q1 2025 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q1 2025 Earnings Conference Call May 13, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executive ...
NEXGEL to Report First Quarter 2025 Financial Results on May 13th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.
NEXGEL, Inc. (NXGL) Q4 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q4 2024 Earnings Conference Call March 24, 2025 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executiv...
NEXGEL Reports Record Fourth Quarter and Full Year 2024 Financial Results
Fourth quarter 2024 revenue totaled $3.04 million, an increase of 181%, as compared to $1.08 million for the same period the prior year
NEXGEL to Report Fourth Quarter and Full Year 2024 Financial Results on March 24th
Management will host a conference call at 4:30 p.m. ET on the same day LANGHORNE, Pa.
NEXGEL to Participate in Webull Consumer Virtual Webinar on February 18, 2025
LANGHORNE, Pa., Feb. 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer
LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL, Inc. (NXGL) Q3 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET Company Participants Maria Honeycutt - Account Director of KCSA Strategic Communications Adam Levy - Chief Exe...
NEXGEL Reports Record Third Quarter 2024 Revenue of $2.94 Million, an Increase of 141% Year-Over-Year and 104% Sequentially
Quarterly revenue growth driven by a sequential increase of 99% in branded consumer products and 103% in contract manufacturing
NEXGEL Announces $2,000,000 Registered Direct Offering
LANGHORNE, Pa., Nov. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: NXGL), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, hig...
NEXGEL to Participate in Upcoming October Investor Conferences
LANGHORNE, Pa., Oct. 11, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL Appoints Kip Crecca to its Scientific Advisory Board
LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, h...
NEXGEL, Inc. (NXGL) Q2 2024 Earnings Call Transcript
NEXGEL, Inc. (NASDAQ:NXGL) Q2 2024 Earnings Conference Call August 14, 2024 4:30 PM ET Company Participants Valter Pinto - Managing Director of KCSA Strategic Communications Adam Levy - Chief Executi...
NEXGEL Reports Record Second Quarter 2024 Revenue of $1.44 Million
LANGHORNE, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. (“NEXGEL” or the “Company”) (NASDAQ: “NXGL”), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and...
NEXGEL to Report Second Quarter 2024 Financial Results on August 14th
Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa.